A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of H021 in Healthy Participants
Latest Information Update: 10 Oct 2024
Price :
$35 *
At a glance
- Drugs H 021 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Jiangsu Carephar Pharmaceutical
- 10 Oct 2024 New trial record